RT Journal Article
SR Electronic
T1 Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.19.22277747
DO 10.1101/2022.07.19.22277747
A1 Camacho, Jorge
A1 Giménez, Estela
A1 Albert, Eliseo
A1 Zulaica, Joao
A1 Álvarez-Rodríguez, Beatriz
A1 Torres, Ignacio
A1 Rusu, Luciana
A1 Burgos, Javier S.
A1 Peiró, Salvador
A1 Vanaclocha, Hermelinda
A1 Limón, Ramón
A1 Jesús Alcaraz, María
A1 Sánchez-Payá, José
A1 Díez-Domingo, Javier
A1 Comas, Iñaki
A1 Gonzáles-Candelas, Fernando
A1 Geller, Ron
A1 Navarro, David
A1 the Valencian Vaccine Research Program (ProVaVac) study group
YR 2022
UL http://medrxiv.org/content/early/2022/07/19/2022.07.19.22277747.abstract
AB Background Studies investigating the cumulative incidence of and immune status against SARS-CoV-2 infection provide valuable information for shaping public health decision-making.Methods The current cross-sectional, population-based study, conducted in April 2022 in the Valencian Community (VC), recruited 935 participants of all ages. Anti-SARS-CoV-2-Receptor Binding Domain-RBD-total antibodies and anti-Nucleocapsid (N)- IgGs were measured by electrochemiluminescence assays. To account for past SARS-CoV-2 infection the VC microbiology registry (RedMiVa) was interrogated. |Quantitation of neutralizing antibodies (NtAb) against the ancestral and Omicron BA.1 and BA.2 (sub)variants by an S-pseudotyped neutralization assay and for enumeration of SARS-CoV-2-S specific-IFNγ-producing CD4+ and CD8+ T cells by Intracellular Cytokine Staining assay was performed in a subset of participants (n=100 and 137, respectively).Findings The weighted cumulative incidence was 51□9% (95% CI, 48□7–55□1), and was inversely related to age. Anti-RBD total antibodies were detected in 906/931 (97□3%) participants, those vaccinated and SARS-CoV-2-experienced (VAC-ex;=442) displaying higher levels (P<0.001) than vaccinated/naïve (VAC-n;(n=472) and non-vaccinated/experienced (UNVAC-ex; n(n=63). Antibody levels correlated inversely with the time elapsed since receipt of last vaccine dose in VAC-n (Rho, -0□52; 95% CI, -0□59 to -0□45; P<0.001) but not in VAC-ex. NtAbs against Omicron BA.1 were detected in 94%, 75% and 50% of VAC-ex, VAC-n and UNVAC-ex groups, respectively, while in 97%, 84% and 40%, against Omicron BA.2. SARS-CoV-2-S-reactive IFN-γ T cells were detected in 73%, 75%, and 64% for VAC-ex, VAC-n, UNVAC-ex, respectively.Interpretation By April 2022 around half of the VC population had been infected with SARS-CoV-2 and due to extensive vaccination display hybrid immunity. The large percentage of participants with detectable functional antibody and T-cell responses against SARS-CoV-2, which may be cross-reactive to some extent, points towards lower expected severity than in previous waves.Funding This research was supported in part by the European Commission NextGenerationEU fund (CSIC’s Global Health Platform).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported in part by the European Commission NextGenerationEU fund (CSIC's Global Health Platform).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Because the survey was carried out under the epidemiological surveillance competences of the Valencian Community Autonomous Government (Law 10/2014, Dec 29 on Public Health of the Valencian Community, Spain), the Research Ethics Committee of the Foundation for the Health and Biomedical Research Promotion of the Valencian Community, Valencia, Spain (Research Ethics Committee of Public Health) waived the need for ethical approval or informed consent (Research Ethics Committee reference: 20220408/02). All personal data were processed under the standards of the Valencia Goverment Health Department, in accordance with the European data protection regulations and the Spanish laws on data protectionI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding author